Ausgabe 1/2015
Inhalt (18 Artikel)
Tailoring treatment in myeloma: are there clues from biology?
Niklas Zojer, Heinz Ludwig
New drugs on the horizon. Treatment of myeloma in 2020, a perspective
Heinz Ludwig, Wolfgang Hilbe, Niklas Zojer
Is more better in myeloma? Treatment intensity and outcome in newly diagnosed myeloma patients
Michael Fillitz, Adelheid Seebacher, Michael Panny
To maintain or not to maintain: treatment forever in myeloma?
Wolfgang Willenbacher, Ella Willenbacher
High-dose chemotherapy and autologous hematopoietic stem cell transplantation in a myeloma patient with terminal renal failure and hepatitis C with high viral load
Niklas Zojer, Michael Gschwantler, Wolfgang Hilbe
Clinical update: B-cell receptor kinase inhibitors in chronic lymphocytic leukemia
Lukas Weiss, Thomas Melchardt, Alexander Egle
A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma
Bahil Ghanim, Mir Alireza Hoda, Thomas Klikovits, Balazs Dome, Michael Grusch, Martin Filipits, Walter Klepetko, Walter Berger, Balazs Hegedus
Optimal follow-up of ovarian cancer patients
Eduard Vrdoljak, Branka Petrić Miše, Tihana Boraska Jelavić, Snježana Tomić, Dinka Šundov, Ante Strikić
Optimal follow-up of endometrial cancer patients
Eduard Vrdoljak, Tihana Boraska Jelavić, Branka Petrić Miše
Optimal follow-up of cervical cancer patients
Eduard Vrdoljak, Tihana Boraska Jelavić, Branka Petrić Miše, Tomislav Omrčen
Radiotherapy for brain metastases: are we getting better?
Leor Zach, Alisa Talianski, Yaakov Richard Lawrence
Predicting drug sensitivity by 3D cell culture models
Arno Amann, Gabriele Gamerith, Julia M. Huber, Marit Zwierzina, Wolfgang Hilbe, Heinz Zwierzina